Seminars in Oncology
Volume 34 , Pages S37-S40 , April 2007

Adjuvant Therapy for Stage II and III Colorectal Cancer

References 

  1. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-258
  2. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med. 1995;122:321–326
  3. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and LV, fluorouracil and levamisole, and fluorouracil, LV, and levamisole in patients with Dukes’ B and C carcinoma of the colon: Results from the National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–3559
  4. Haller DG, Catalano PJ, MacDonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five year report of INT-0089. [abstract 982] Proc Am Soc Clin Oncol. 1998;17:356a
  5. O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300
  6. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet. 2000;355:1588–1596
  7. de Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose LV and fluorouracil bolus with bimonthly high-dose LV and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol. 1997;15:808–815
  8. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;16:1859–1865
  9. Poplin E, Benedetti J, Estes N, et al. Phase III randomized trial of bolus 5-FU/LV/levamisole versus continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 941/INT-0153). [abstr 931] Proc Am Soc Clin Oncol. 2000;19:240a
  10. André T, Colin P, Louvet C, et al. Bimonthly regimen of 5-fluorouracil and leucovorin (LV5FU2) as adjuvant therapy in stage II and II colon cancer: 4-year results of a randomized trial. J Clin Oncol. 2003;21:2896–2903
  11. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704
  12. Cassidy J, Twelves C, Nowacki MP, et al. Improved safety of capecitabine versus bolus 5-fluorouracil/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). 2004;[abstr 219A]. ASCO Gastrointestinal Cancer Symposium, January, Florida
  13. Gray RG, Barnwell J, Hills R, et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. [abstr 3501A] J Clin Oncol. 2004;22:245s
  14. Saltz LB, Cox JV, Blanke C, et al. Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914
  15. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). [abstr 3500A] J Clin Oncol. 2004;22:246
  16. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). [abstr 3502A] J Clin Oncol. 2005;23:246s
  17. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3). [abstr 8A] J Clin Oncol. 2005;23:3s
  18. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol. 2002;20:2445–2550
  19. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus LV, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  20. de Gramont A, Figer A, Seymour M, et al. LV and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  21. de Gramont A, Boni C, Navarro J, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. [abstr 3501A] J Clin Oncol. 2005;23:246s
  22. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  23. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. [abstr 3500A] J Clin Oncol. 2005;23:246s

PII: S0093-7754(07)00020-6

doi: 10.1053/j.seminoncol.2007.01.004

Seminars in Oncology
Volume 34 , Pages S37-S40 , April 2007

Article Tools

* Image Usage & Resolution